Role of HIV infection duration and CD4 cell level at initiation of combination anti-retroviral therapy on risk of failure.
<h4>Background</h4>The development of HIV drug resistance and subsequent virological failure are often cited as potential disadvantages of early cART initiation. However, their long-term probability is not known, and neither is the role of duration of infection at the time of initiation....
Main Authors: | , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24086588/?tool=EBI |
id |
doaj-35262eac5cb748d88f39bf78f2fe381c |
---|---|
record_format |
Article |
spelling |
doaj-35262eac5cb748d88f39bf78f2fe381c2021-03-03T22:51:41ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-0189e7560810.1371/journal.pone.0075608Role of HIV infection duration and CD4 cell level at initiation of combination anti-retroviral therapy on risk of failure.Sara LodiAndrew PhillipsSarah FidlerDavid HawkinsRichard GilsonKen McLeanMartin FisherFrank PostAnne M JohnsonLouise Walker-NthendaDavid DunnKholoud PorterUK Register of HIV<h4>Background</h4>The development of HIV drug resistance and subsequent virological failure are often cited as potential disadvantages of early cART initiation. However, their long-term probability is not known, and neither is the role of duration of infection at the time of initiation.<h4>Methods</h4>Patients enrolled in the UK Register of HIV seroconverters were followed-up from cART initiation to last HIV-RNA measurement. Through survival analysis we examined predictors of virologic failure (2HIV-RNA ≥400 c/l while on cART) including CD4 count and HIV duration at initiation. We also estimated the cumulative probabilities of failure and drug resistance (from the available HIV nucleotide sequences) for early initiators (cART within 12 months of seroconversion).<h4>Results</h4>Of 1075 starting cART at a median (IQR) CD4 count 272 (190,370) cells/mm(3) and HIV duration 3 (1,6) years, virological failure occurred in 163 (15%). Higher CD4 count at initiation, but not HIV infection duration at cART initiation, was independently associated with lower risk of failure (p=0.033 and 0.592 respectively). Among 230 patients initiating cART early, 97 (42%) discontinued it after a median of 7 months; cumulative probabilities of resistance and failure by 8 years were 7% (95% CI 4,11) and 19% (13,25), respectively.<h4>Conclusion</h4>Although the rate of discontinuation of early cART in our cohort was high, the long-term rate of virological failure was low. Our data do not support early cART initiation being associated with increased risk of failure and drug resistance.https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24086588/?tool=EBI |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Sara Lodi Andrew Phillips Sarah Fidler David Hawkins Richard Gilson Ken McLean Martin Fisher Frank Post Anne M Johnson Louise Walker-Nthenda David Dunn Kholoud Porter UK Register of HIV |
spellingShingle |
Sara Lodi Andrew Phillips Sarah Fidler David Hawkins Richard Gilson Ken McLean Martin Fisher Frank Post Anne M Johnson Louise Walker-Nthenda David Dunn Kholoud Porter UK Register of HIV Role of HIV infection duration and CD4 cell level at initiation of combination anti-retroviral therapy on risk of failure. PLoS ONE |
author_facet |
Sara Lodi Andrew Phillips Sarah Fidler David Hawkins Richard Gilson Ken McLean Martin Fisher Frank Post Anne M Johnson Louise Walker-Nthenda David Dunn Kholoud Porter UK Register of HIV |
author_sort |
Sara Lodi |
title |
Role of HIV infection duration and CD4 cell level at initiation of combination anti-retroviral therapy on risk of failure. |
title_short |
Role of HIV infection duration and CD4 cell level at initiation of combination anti-retroviral therapy on risk of failure. |
title_full |
Role of HIV infection duration and CD4 cell level at initiation of combination anti-retroviral therapy on risk of failure. |
title_fullStr |
Role of HIV infection duration and CD4 cell level at initiation of combination anti-retroviral therapy on risk of failure. |
title_full_unstemmed |
Role of HIV infection duration and CD4 cell level at initiation of combination anti-retroviral therapy on risk of failure. |
title_sort |
role of hiv infection duration and cd4 cell level at initiation of combination anti-retroviral therapy on risk of failure. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2013-01-01 |
description |
<h4>Background</h4>The development of HIV drug resistance and subsequent virological failure are often cited as potential disadvantages of early cART initiation. However, their long-term probability is not known, and neither is the role of duration of infection at the time of initiation.<h4>Methods</h4>Patients enrolled in the UK Register of HIV seroconverters were followed-up from cART initiation to last HIV-RNA measurement. Through survival analysis we examined predictors of virologic failure (2HIV-RNA ≥400 c/l while on cART) including CD4 count and HIV duration at initiation. We also estimated the cumulative probabilities of failure and drug resistance (from the available HIV nucleotide sequences) for early initiators (cART within 12 months of seroconversion).<h4>Results</h4>Of 1075 starting cART at a median (IQR) CD4 count 272 (190,370) cells/mm(3) and HIV duration 3 (1,6) years, virological failure occurred in 163 (15%). Higher CD4 count at initiation, but not HIV infection duration at cART initiation, was independently associated with lower risk of failure (p=0.033 and 0.592 respectively). Among 230 patients initiating cART early, 97 (42%) discontinued it after a median of 7 months; cumulative probabilities of resistance and failure by 8 years were 7% (95% CI 4,11) and 19% (13,25), respectively.<h4>Conclusion</h4>Although the rate of discontinuation of early cART in our cohort was high, the long-term rate of virological failure was low. Our data do not support early cART initiation being associated with increased risk of failure and drug resistance. |
url |
https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24086588/?tool=EBI |
work_keys_str_mv |
AT saralodi roleofhivinfectiondurationandcd4celllevelatinitiationofcombinationantiretroviraltherapyonriskoffailure AT andrewphillips roleofhivinfectiondurationandcd4celllevelatinitiationofcombinationantiretroviraltherapyonriskoffailure AT sarahfidler roleofhivinfectiondurationandcd4celllevelatinitiationofcombinationantiretroviraltherapyonriskoffailure AT davidhawkins roleofhivinfectiondurationandcd4celllevelatinitiationofcombinationantiretroviraltherapyonriskoffailure AT richardgilson roleofhivinfectiondurationandcd4celllevelatinitiationofcombinationantiretroviraltherapyonriskoffailure AT kenmclean roleofhivinfectiondurationandcd4celllevelatinitiationofcombinationantiretroviraltherapyonriskoffailure AT martinfisher roleofhivinfectiondurationandcd4celllevelatinitiationofcombinationantiretroviraltherapyonriskoffailure AT frankpost roleofhivinfectiondurationandcd4celllevelatinitiationofcombinationantiretroviraltherapyonriskoffailure AT annemjohnson roleofhivinfectiondurationandcd4celllevelatinitiationofcombinationantiretroviraltherapyonriskoffailure AT louisewalkernthenda roleofhivinfectiondurationandcd4celllevelatinitiationofcombinationantiretroviraltherapyonriskoffailure AT daviddunn roleofhivinfectiondurationandcd4celllevelatinitiationofcombinationantiretroviraltherapyonriskoffailure AT kholoudporter roleofhivinfectiondurationandcd4celllevelatinitiationofcombinationantiretroviraltherapyonriskoffailure AT ukregisterofhiv roleofhivinfectiondurationandcd4celllevelatinitiationofcombinationantiretroviraltherapyonriskoffailure |
_version_ |
1714812107947507712 |